Belapectin Shows Significant Liver Stiffness Reduction in Galectin Therapeutics Trial
summarizeSummary
Galectin Therapeutics announced its first-quarter 2026 financial results and provided a significant business update, detailing positive clinical data from its NAVIGATE Phase 2b/3 trial for belapectin. The drug demonstrated statistically significant reductions in liver stiffness measurements and a decreased proportion of patients experiencing clinically meaningful worsening, suggesting a reduction in fibrosis progression for MASH cirrhosis patients. This positive clinical development is critical for the company's lead therapeutic candidate. While the financial results were largely covered by an earlier 10-Q filing, the detailed clinical data is new and highly material. The company also confirmed a cash runway through May 2027. Investors should monitor upcoming data presentations at EASL later this month and a planned Type-C meeting with the FDA this quarter, which are key catalysts for the program's future development and potential partnership discussions.
At the time of this announcement, GALT was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.7M. The 52-week trading range was $1.21 to $7.13. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.